On October 7, Eli Lilly rose 3.03% in regular trading, reaching $1192.53 with turnover of $8.04 billion. The advance was fueled by continued bullish calls from Wall Street analysts and a flurry of positive updates across its obesity pipeline.

Morgan Stanley raised its price target on Eli Lilly to $1,430 from $1,419, reaffirming an overweight rating, while JPMorgan previously lifted its target to $1,500. On the clinical front, UBS highlighted new data showing the company's next-generation oral obesity treatments achieved over 20% weight loss in some studies, with the EloraTZP combination delivering up to 23% weight reduction in a Phase 2b trial. Separately, the oral GLP-1 drug Foundayo met its primary endpoint in a Phase 3 study. The company's third-quarter earnings are scheduled for October 29 before market open, with consensus EPS expectations of $9.83.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)